
First Ascent Biomedical creates personalized cancer treatment plans by testing how a patient’s tumor and resistant cells respond to drugs and using AI to rank effective options. Their Drug Prediction Platform (DxPP) uses a proprietary cell enrichment method to grow tumor bulk and chemo‑resistant cells, performs drug sensitivity testing across hundreds of FDA‑approved drugs, and integrates DNA/RNA sequencing, mutation analysis, and causal machine learning to generate combination and monotherapy recommendations. The company operates as a biotech platform serving oncology physicians and patients with actionable reports delivered in about 10 days. First Ascent supports clinical and drug‑development workflows and partners with cancer centers and industry for validation studies and sponsored research.

First Ascent Biomedical creates personalized cancer treatment plans by testing how a patient’s tumor and resistant cells respond to drugs and using AI to rank effective options. Their Drug Prediction Platform (DxPP) uses a proprietary cell enrichment method to grow tumor bulk and chemo‑resistant cells, performs drug sensitivity testing across hundreds of FDA‑approved drugs, and integrates DNA/RNA sequencing, mutation analysis, and causal machine learning to generate combination and monotherapy recommendations. The company operates as a biotech platform serving oncology physicians and patients with actionable reports delivered in about 10 days. First Ascent supports clinical and drug‑development workflows and partners with cancer centers and industry for validation studies and sponsored research.
Headquarters: Miami, Florida
Founded: 2018
Focus: AI-driven personalized combination cancer therapy recommendations
Product: Drug Prediction Platform (DxPP) — ex vivo drug sensitivity testing + sequencing + causal ML
Recent funding: Announced $6M venture/seed round (Jan 13, 2025) plus 2025 grants
Personalized oncology treatment selection; resistance-informed combination therapy design.
2018
Biotechnology
$6,000,000
Reported venture/seed round announced Jan 13, 2025
Grant announced Mar 4, 2025
Grant announced Jun 5, 2025
“Includes venture investors (Vidal Duart Enterprises, Techstars) and grant funders (Florida Department of Health, Fight Colorectal Cancer); additional named investors include IAG Capital Partners and Secure Erie Accelerator.”